Login / Signup

Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.

Ayaka SaitoHideki TeraiTae-Jung KimKatsura EmotoRyutaro KawanoKohei NakamuraHideyuki HayashiHatsuyo TakaokaAkihiko OgataKatsuhito KinoshitaFumimaro ItoLisa ShigematsuMasahiko OkadaTakahiro FukushimaAkifumi MitsuishiTaro ShinozakiKeiko OhginoShinnosuke IkemuraHiroyuki YasudaIchiro KawadaKenzo SoejimaHiroshi NishiharaKoichi Fukunaga
Published in: Cancer medicine (2024)
Even if sufficient tumor samples are obtained, rare EGFR mutations (which are excluded from the ODxTT's genetic mutation list) might not be detected using the current ODxTT system due to the program used for sequence analysis. However, such rare EGFR mutations can still be accurately detected on ODxTT's sequence data using next-generation sequencing.
Keyphrases